Lin Junhao, Chen Zhi, Li Zuan, Nong Deyong, Li Ximing, Huang Guihai, Hao Nan, Liang Jianbo, Li Wei
Department of Urology, The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, Guangxi Zhuang Autonomous Region 530021, P.R. China.
Oncol Rep. 2021 Sep;46(3). doi: 10.3892/or.2021.8147. Epub 2021 Jul 23.
Prostate cancer (PCa) is the most common cancer type in men worldwide. Currently, the management of metastatic PCa (mPCa) remains a challenge to urologists. The analysis of hub genes and pathways may facilitate the understanding of the molecular mechanism of PCa. In the present study, to identify the hub genes in the mPCa, the three datasets GSE3325, GSE6919 and GSE38241 were downloaded from the platform of the Gene Expression Omnibus and function enrichment analysis of differentially expressed genes (DEGs) was performed. A total of 168 DEGs were obtained and the DEGs were significantly enriched in 'cell junction' and 'cell adhesion', among others. The Kyoto Encyclopedia of Genes and Genomes pathway enrichment analysis demonstrated that DEGs were enriched in three pathways including 'focal adhesion', 'renal cell carcinoma' and 'Hippo signaling pathway'. The results of the protein‑protein interaction network revealed that the hub genes in mPCa were separately PTEN, Rac GTPase‑activating protein 1, protein regulator of cytokinesis 1, PDZ binding kinase, centromere‑associated protein E, NUF2 component of NDC80 kinetochore complex, TPX2 microtubule nucleation factor, SOX2, CD44 and ubiquitin‑like with PHD and ring finger domains 1. As a hub gene, CD44 was differentially expressed in PCa, as determined by Oncomine analysis. Further experiments demonstrated that SB‑3CT, a selective matrix metalloproteinase inhibitor that has been reported to block CD44 cleavage and inhibit the downstream signaling pathway, suppressed the tumorigenicity of PCa cells by decreasing the expression levels of pyruvate dehydrogenase kinase 1 and 6‑phosphofructo‑2‑kinase/fructose‑2,6‑biphosphatase 4. Moreover, the combination therapy with SB‑3CT and docetaxel was more effective in inhibiting PCa compared with monotherapy. In conclusion, the identification of DEGs and the experimental results helped to elucidate the molecular mechanisms of PCa and provided a potential strategy for the treatment of PCa.
前列腺癌(PCa)是全球男性中最常见的癌症类型。目前,转移性前列腺癌(mPCa)的治疗仍然是泌尿外科医生面临的挑战。对核心基因和信号通路的分析可能有助于理解PCa的分子机制。在本研究中,为了鉴定mPCa中的核心基因,从基因表达综合数据库平台下载了三个数据集GSE3325、GSE6919和GSE38241,并对差异表达基因(DEGs)进行了功能富集分析。共获得168个DEGs,这些DEGs在“细胞连接”和“细胞黏附”等方面显著富集。京都基因与基因组百科全书通路富集分析表明,DEGs在包括“粘着斑”、“肾细胞癌”和“河马信号通路”在内的三条通路中富集。蛋白质-蛋白质相互作用网络的结果显示,mPCa中的核心基因分别为PTEN、Rac GTP酶激活蛋白1、胞质分裂蛋白调节剂1、PDZ结合激酶、着丝粒相关蛋白E、NDC80动粒复合体的NUF2成分、TPX2微管成核因子、SOX2、CD44和具有PHD和指环结构域的泛素样蛋白1。作为一个核心基因,通过Oncomine分析确定CD44在PCa中差异表达。进一步的实验表明,SB-3CT是一种选择性基质金属蛋白酶抑制剂,据报道可阻断CD44裂解并抑制下游信号通路,通过降低丙酮酸脱氢酶激酶1和6-磷酸果糖-2-激酶/果糖-2,6-二磷酸酶4的表达水平来抑制PCa细胞的致瘤性。此外,与单一疗法相比,SB-3CT与多西他赛联合治疗在抑制PCa方面更有效。总之,DEGs的鉴定和实验结果有助于阐明PCa的分子机制,并为PCa的治疗提供了潜在策略。